From Wikipedia, the free encyclopedia
Chemical compound
Hetrombopag
INN : Hetrombopag
Trade names Hengqu Other names Rafutrombopag olamine; rafutrombopag ethanolamine; hetrombopag; SHR-8735; SHR8735
Routes of administration Oral
Legal status
In general: ℞ (Prescription only)
5-[2-Hydroxy-3-[[5-methyl-3-oxo-2-(5,6,7,8-tetrahydronaphthalen-2-yl)-1H -pyrazol-4-yl]diazenyl]phenyl]furan-2-carboxylic acid
CAS Number
PubChem
CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Formula C 25 H 22 N 4 O 5
Molar mass 458.474 g·mol−1 3D model (
JSmol )
CC1=C(C(=O)N(N1)C2=CC3=C(CCCC3)C=C2)N=NC4=CC=CC(=C4O)C5=CC=C(O5)C(=O)O
InChI=InChI=1S/C25H22N4O5/c1-14-22(24(31)29(28-14)17-10-9-15-5-2-3-6-16(15)13-17)27-26-19-8-4-7-18(23(19)30)20-11-12-21(34-20)25(32)33/h4,7-13,28,30H,2-3,5-6H2,1H3,(H,32,33)
Key:YATJUTCKRWETAB-UHFFFAOYSA-N
Hetrombopag (also known as rafutrombopag ; trade name Hengqu ) is a pharmaceutical drug for the treatment of
thrombocytopenia and
anemia .
[1]
[2]
[3]
It is a non-peptide small‐molecule
thrombopoietin receptor agonist.
[4]
In China, it is approved for second-line treatment for primary
immune thrombocytopenic purpura (ITP) and severe
aplastic anemia (SAA) in adults.
[4]
References
^ Mei H, Chen X, Zhou J, Luo J, Shi Q, Liu J, et al. (January 2022).
"Safety and efficacy of hetrombopag in patients with chronic immune thrombocytopenia: a single-arm, open-label, multi-center phase 1 study" . Annals of Translational Medicine . 10 (2): 30.
doi :
10.21037/atm-21-4361 .
PMC
8848441 .
PMID
35282136 .
^ Mei H, Liu X, Li Y, Zhou H, Feng Y, Gao G, et al. (February 2021).
"A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia" . Journal of Hematology & Oncology . 14 (1): 37.
doi :
10.1186/s13045-021-01047-9 .
PMC
7905908 .
PMID
33632264 .
^ Chang H, Pan L, Jia Y, Xiang B, Huang X, Guo Y, et al. (2023). "Effectiveness and Safety of Hetrombopag-Containing Therapy in Patients with Severe Aplastic Anemia: A Multicenter Real-World Study". Blood . 142 : 5631.
doi :
10.1182/blood-2023-185469 .
^
a
b Syed YY (September 2021). "Hetrombopag: First Approval". Drugs . 81 (13): 1581–1585.
doi :
10.1007/s40265-021-01575-1 .
PMID
34357499 .